AddLife AB Class B (ADDLF)
OTHER OTC:ADDLF
Want to see ADDLF full AI Analyst Report?
ADDLF Stock Chart & Stats
$16.81
$0.00(0.00%)
At close: 4:00 PM EDT
$16.81
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$11.75 - $24.52
Previous CloseN/A
Volume1.00
Average Volume (3M)0.00
Market Cap
$1.88B
Enterprise Value$20.79B
Total Cash (Recent Filing)$771.00M
Total Debt (Recent Filing)$4.82B
Price to Earnings (P/E)33.5
Beta0.86
Next Earnings
Jul 16, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)4.65
Shares Outstanding117,877,460
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)3.56
Price to Sales (P/S)1.86
P/FCF Ratio17.04
Enterprise Value/Market Cap11.08
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit5.23
Enterprise Value/Ebitda14.90
Forecast
1Y Price Target
$17.86Price Target Upside6.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.65
Revenue Forecast (FY)$1.17B
Bulls Say, Bears Say
Bulls Say
Cash Generation & ConversionSustained strong operating and free cash flow gives AddLife durable self-funding capacity for capex, working-capital cushions and bolt-on M&A without heavy equity issuance. High cash conversion also supports deleveraging and returns to stakeholders through cycles.
Improving MarginsConsistent margin improvement driven by price management, higher‑margin product mix, pruning low-margin SKUs and a growing share of own products indicates structural uplift in profitability that sustains operating cash and resilience versus cyclic instrument sales.
Deleveraging And M&A CapacityMaterial reduction in net debt and sub-target leverage restore balance-sheet flexibility. This permits disciplined bolt-on acquisitions to drive scale and portfolio upgrade while keeping leverage in a range that supports investment without destabilizing credit metrics.
Bears Say
Weak Revenue GrowthStagnant top-line and a sharp TTM revenue decline signal structural demand challenges in key end markets. Without sustained organic growth, margin gains and cash flow could be harder to maintain long term and the firm may increasingly rely on acquisitions to meet growth targets.
Meaningful Remaining LeverageAlthough leverage has improved, the company still carries significant absolute debt which reduces financial flexibility versus low‑leverage peers. In downturns higher interest or refinancing risk could constrain investment, M&A cadence, or require prioritized cash allocation.
End-market And Portfolio RisksExposure to elective surgery cycles, academic and pharma spending and currency swings creates structural revenue volatility. Recent divestment/hand-over trimmed recurring sales and replacement will be gradual, making organic stability dependent on winning new tenders and markets.
AddLife AB News
ADDLF FAQ
What was AddLife AB Class B’s price range in the past 12 months?
AddLife AB Class B lowest stock price was $11.75 and its highest was $24.52 in the past 12 months.
What is AddLife AB Class B’s market cap?
AddLife AB Class B’s market cap is $1.88B.
When is AddLife AB Class B’s upcoming earnings report date?
AddLife AB Class B’s upcoming earnings report date is Jul 16, 2026 which is in 69 days.
How were AddLife AB Class B’s earnings last quarter?
AddLife AB Class B released its earnings results on Apr 28, 2026. The company reported $0.114 earnings per share for the quarter, missing the consensus estimate of $0.156 by -$0.042.
Is AddLife AB Class B overvalued?
According to Wall Street analysts AddLife AB Class B’s price is currently Undervalued.
Does AddLife AB Class B pay dividends?
AddLife AB Class B pays a Annually dividend of $0.079 which represents an annual dividend yield of 0.2%. See more information on AddLife AB Class B dividends here
What is AddLife AB Class B’s EPS estimate?
AddLife AB Class B’s EPS estimate is 0.14.
How many shares outstanding does AddLife AB Class B have?
AddLife AB Class B has 117,877,460 shares outstanding.
What happened to AddLife AB Class B’s price movement after its last earnings report?
AddLife AB Class B reported an EPS of $0.114 in its last earnings report, missing expectations of $0.156. Following the earnings report the stock price went down -1.955%.
Which hedge fund is a major shareholder of AddLife AB Class B?
Currently, no hedge funds are holding shares in ADDLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AddLife AB Class B
AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments. This segment also offers support, maintenance, advice, and training services. The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities. It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
ADDLF Company Deck
ADDLF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone: clear and continuous margin improvement, strong operating cash flow, meaningful net-debt reduction (net debt-to-EBITDA 2.2), and an active, disciplined M&A pipeline. These positives offset material near-term headwinds from currency effects, some weaker instrument and geographic pockets, and one-off impacts from strikes and a divestment/hand-over of a UK endoscopy business. Management emphasized ongoing margin initiatives, portfolio upgrades and confidence in picking up acquisition activity in 2026.View all ADDLF earnings summariesADDLF Stock 12 Month Forecast
Average Price Target
$17.86
▲(6.25% Upside)
Technical Analysis
Ownership Overview
―
Insiders
11.16% Mutual Funds
― Other Institutional Investors
84.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---